Bovine Respiratory Disease Treatment; Effectiveness of Treatment Depends Primarily On Early Recognition and Treatment

 

Bovine respiratory disease treatment can include the recommendation to use third-generation cephalosporins, fluoroquinolones, florfenicol (relative to chloramphenicol), and/or tilmicosin, a macrolide antibiotic. The therapeutic strategy of bovine respiratory disease often involves a combination of an antibiotic with an anti-inflammatory agent. There are many antimicrobials labeled for treating BRD. The most common antimicrobials used for the initial treatment of respiratory disease were tilmicosin, florfenicol, and tetracyclines.

Bovine Respiratory Disease Treatment is a general term for respiratory disease in cattle caused by a range of factors, singly or in combination. BRD affects the lower respiratory tract/lungs (pneumonia) or upper respiratory tract (rhinitis, tracheitis, bronchitis). Bovine respiratory disease complex (BRDC) is a leading cause of morbidity and mortality in feedlot cattle. The disease is considered a multifactorial disorder caused by a combination of viral and bacterial pathogens. The disease develops as a result of complex interactions between environmental factors, host factors, and pathogens.

The majority of these primary BRD pathogens are highly contagious viruses that can easily spread between herds, directly through animal contact/movement, or indirectly through contaminated environments or fomites brought between herds. Bovine respiratory disease (BRD) can lead to significant economic losses for individual beef cattle feedlot producers through mortality and morbidity. BRD is a common endemic disease among North American feedlot cattle. It is the most costly disease of beef cattle in North America.

Bovine respiratory disease complex, also known as shipping fever or bronchopneumonia, is a leading cause of illness and death in U.S. feedlots. Therefore, there is an increasing demand for Bovine Respiratory Disease Treatment in the United States. In March 2022, Merck Animal Health announced it has received U.S. FDA approval of AROVYN (tulathromycin injection), a broad-spectrum, prescription antibiotic that treats the major organisms associated with bovine respiratory disease (BRD), foot rot, and pinkeye.